T. Hartman et al. / Tetrahedron: Asymmetry 23 (2012) 1571–1583
1581
calculated for hexahydrate), PyBOP (136 mg; 219
(83 L; 0.49 mmol) by the same procedure as described for 28.
Conjugate 31 was isolated as yellow amorphous material
l
mol), and DIPEA
145.81 (fl-C-5a); 147.40 (fl-C-10a); 154.32 (fl-C-2); 164.05 (fl-C-
4); 172.92 (NH–CO–CH2); MS (ESI) calcd for [M+Na]+ m/z 1468.5;
found 1468.8. UV–VIS (phosphate buffer pH 2.0): 322 nm,
376 nm. Anal. Calcd for C57H83N5O38.8H2O: C, 43.05; H, 6.27; N,
4.40. Found C, 43.18; H, 6.28; N, 4.69.
l
a
(195 mg; 52%, calculated for pentahydrate). 1H NMR (D2O, 37 °C,
600.1 MHz), d: 3.28, 3.54–3.85(5H) and 4.07 (7 ꢁ m, 1H, H-5);
3.435, 3.50, 3.53, 3.67–3.75(4H), 3.82–3.90(6H) and 3.96 (m, 14H,
H-6); 3.482, 3.504, 3.535-3.65(3H), 3.542 and 3.573 (7 ꢁ m, 7H,
H-4); 3.538, 3.607, 3.611, 3.613, 3.622, 3.664 and 3.714 (7 ꢁ m,
7H, H-2); 3.706, 3.794–3.847(4H), 3.959 and 4.00 (7 ꢁ m, 7H, H-
3); 3.75 (s, 3H, N-CH3); 4.84 and 4.96 (2 ꢁ d, 2H, J = 16.0 Hz, N–
CH2–CO); 4.944, 4.972, 5.013, 5.043, 5.062, 5.082 and 5.088
(7 ꢁ d, 7H, J = 3.8 Hz, H-1); 7.97 (ddd, 1H, J = 8.5, 6.8 and 1.4 Hz,
fl-H-7); 8.11 (dd, 1H, J = 8.6, 6.8 and 1.4 Hz, fl-H-8); 8.16 (dd, 1H,
J = 8.6 and 1.4 Hz, fl-H-9); 8.28 (dd, 1H, J = 8.5 and 1.4 Hz, fl-H-6);
13C NMR (D2O, 37 °C, 150.9 MHz), d: 32.21 (N–CH3); 43.23, 62.62,
62.70, 62.76, 62.77, 62.80 and 62.82 (7 ꢁ C-6); 47.30 (N–CH2–
CO); 73.32, 74.39, 74.41(2C), 74.46 and 74.53(2C) (7 ꢁ C-5);
74.55, 74.67(2C), 74.68, 74.72, 74.81 and 74.82 (7 ꢁ C-2);
75.70(2C), 75.77, 75.80(2C), 75.83 and 75.86 (7 ꢁ C-3); 82.93,
83.37, 83.60(2C), 83.65, 83.89 and 86.00 (7 ꢁ C-4); 104.10,
104.31, 104.54, 104.55, 104.61, 104.64 and 104.66 (7 ꢁ C-1);
130.09 (fl-C-9); 132.21 (fl-C-4a); 132.32 (fl-C-6); 132.88 (fl-C-7);
137.61 (fl-C-8); 141.95 (fl-C-5a); 145.80 (fl-C-9a); 148.20 (fl-C-
10a); 153.86 (fl-C-2); 163.49 (fl-C-4); 171.81 (N-CO-CH2). HR-MS
(ESI+) calcd for C55H79N5O37 [M+H+] m/z 1401.45; found 1401.45.
UV–VIS (phosphate buffer pH 2.0) 331 nm, 383 nm. Anal. Calcd
for C55H79N5O37 5H2O: C, 44.27; H, 6.01; N, 4.69. Found: C,
44.02; H, 5.99; N, 4.56.
4.6.2. N-[2-(b-Cyclodextrin-3-O-yl)ethyl]-2-(10-methylisoallo-
xazine-3-yl)acetamide 33
This compound was prepared from the hydrochloride salt of
amine 24 (18.9 mg; 0.014 mmol), PyBOP (9.75 mg; 0.019 mmol),
DIPEA (14 lL; 0.08 mmol), and 2-(10-methylisoalloxazin-3-yl)ace-
tic acid (4.11 mg; 0.014 mmol) by the same procedure as described
for 32. Conjugate 33 was isolated as a yellow amorphous material
(18 mg; 77%). 1H NMR (D2O, 27 °C, 600.1 MHz, 40 °C), d: 3.13, 3.55
and 3.59–3.64(5H) (7 ꢁ m, 7H, H-2); 3.52–3.58(5H), 3.62 and 3.74
(7 ꢁ m, 7H, H-4); 3.55–3.94 (14 ꢁ m, 14H, H-3 and H-5); 3.74–3.87
(14 ꢁ m, 14H, H-6); 4.63, 4.95, 5.044, 5.049, 5.051 and 5.055(2H)
(7 ꢁ d, 7H, J = 3.8 Hz, H-1); 3.37 and 3.51 (2 ꢁ m, 2H, CH2–CH2–
NH); 3.92 and 4.11 (2 ꢁ m, 2H, O–CH2–CH2); 4.17 (s, 3H, N–CH3);
4.73 and 4.83 (2 ꢁ d, 2H, J = 16.5 Hz, N–CH2–CO); 7.83 (ddd, 1H,
J = 8.3, 7.1 and 1.2 Hz, fl-H-8); 8.03 (dd, 1H, J = 8.8 and 1.2 Hz, fl-
H-6); 8.11 (ddd, 1H, J = 8.8, 7.1 and 1.6 Hz, fl-H-7); 8.21 (dd, 1H,
J = 8.3 and 1.6 Hz, fl-H-9). 13C NMR (D2O, 27 °C, 150.9 MHz,
40 °C), d: 35.59 (N–CH3); 43.25 (CH2–CH2–N); 47.07 (CO–CH2–N);
62.54, 62.82(5C) and 62.94 (7 ꢁ C-6); 72.76 (O–CH2–CH2); 74.15,
74.20, 74.24, 74.34, 74.36(2C) and 82.96 (7 ꢁ C-5); 74.38, 74.47,
74.56, 74.62(2C), 74.74 and 74.80 (7 ꢁ C-3); 74.98, 75.57, 75.62,
75.65, 75.68(2C) and 75.71 (7 ꢁ C-2); 81.16, 83.56, 83.57, 83.60,
83.68(2C), and 84.20 (7 ꢁ C-4); 103.85, 104.05, 104.30, 104.34,
104.39(2C), and 104.43 (7 ꢁ C-1); 119.41 (fl-C-6); 130.87 (fl-C-8);
134.39 (fl-C-9); 136.26 (fl-C-9a); 138.45 (fl-C-5a); 138.90 (fl-C-
4a); 139.94 (fl-C-7); 152.17 (fl-C-10a); 159.43 (fl-C-2); 163.74 (fl-
C-4); 172.48 (N–CO–CH2). MS (ESI) calcd for C57H83N5O38
[M+Na]+ m/z 1468.5, found 1468.8. UV–VIS (phosphate buffer pH
4.6. Synthesis of conjugates 32 and 33
4.6.1. N-[2-(b-Cyclodextrin-3I-O-yl)ethyl]-2-(3-methylalloxazine-
1-yl)acetamide 32
The TFA salt of amine 24 (24 mg; 0.016 mmol, calculated for the
decahydrate) was transformed into the HCl salt by passing its solu-
tion through Dowex 18 (0.1 mL, in the Clꢀ cycle). The residue
(20.5 mg) was dried in vacuo and then dissolved in dry DMF
(0.5 mL). To this solution, PyBOP (9.9 mg; 0019 mmol), DIPEA
(0.15 mL; 0.086 mmol), and 2-(3-methylalloxazin-1-yl)ethanoic
acid 16 were added subsequently with stirring and under an argon
atmosphere. The mixture was allowed to react for 20 h. The solvent
was then evaporated under reduced pressure and the product was
isolated by chromatography (reversed phase, MeOH–H2O, gradient
from 5:95 to 30:70). White amorphous solid (18 mg, 71%, calcd for
octahydrate). 1H NMR (D2O, 40 °C, 600.1 MHz), d: 2.22, 3.468,
3.762, 3.967, 4.077, 4.45 and 4.463 (7 ꢁ m, 7H, H-3); 2.803,
3.452, 3.465, 3.86, 3.905, 3.908 and 4.064 (7 ꢁ m, 7H, H-5); 3.15,
3.49, 3.531, 3.626, 3.721, 3.907 and 4.064 (7 ꢁ m, 7H, H-4);
3.434, 3.546, 3.559, 3.601, 3.724, 3.755 and 3.832 (7 ꢁ m, 7H, H-
2); 3.550, 3.598, 3.686, 3.806, 3.875(2H), 3.90, 3.903, 3.95, 3.976,
3.986, 4.036, 4.109 and 4.175 (14 ꢁ m, 14H, H-6); 4.811, 4.920,
5.002, 5.078, 5.123, 5.154 and 5.188 (7 ꢁ d, 7H, J = 3.5 Hz, H-1);
3.32 and 3.66 (2 ꢁ m, 2H, CH2–CH2–NH); 3.59 (s, 3H, N–CH3);
3.76 and 4.18 (2 ꢁ m, 2H, O–CH2–CH2); 5.11 and 5.45 (2 ꢁ d,
J = 16.4 Hz, N–CH2–CO); 7.87 (ddd, 1H, J = 8.6, 6.9 and 1.3 Hz, fl-
H-8); 8.04 (ddd, 1H, J = 8.5, 6.9 and 1.4 Hz, fl-H-7); 8.27 (dd, 1H,
J = 8.5 and 1.3 Hz, fl-H-6); 8.36 (dd, 1H, J = 8.6 and 1.4 Hz, fl-H-9);
13C NMR (D2O, 40 °C, 150.9 MHz), d: 31.97 (N–CH3); 43.42 (CH2–
CH2–N); 47.97 (CO–CH2–N); 62.67, 62.89, 62.91, 62,99, 63,04,
63,10 and 63,13 (7 ꢁ C-6); 74.11, 74.58, 74.63(2C), 74.82, 74.89
and 76.19 (7 ꢁ C-2); 74.14, 75.14, 75.28, 75.74, 75.83, 75.90 and
82.13 (7 ꢁ C-5); 74.63, 74.86, 75.50(2C), 75.57, 76.00 and 76.29
(7 ꢁ C-3); 76.38 (O–CH2–CH2); 83.29, 83.70, 83.72, 83.80, 83.92,
84.45 and 85.00 (7 ꢁ C-4); 104.27, 104.49, 104.56, 104.54,
104.66(2C) and 105.27 (7 ꢁ C-1); 130.27 (fl-C-6); 132.26 (fl-C-8);
132.36 (fl-C-9); 132.57 (fl-C-4a); 136.82 (fl-C-7); 142.46 (fl-C-9a);
2.0): 347 nm, 432 nm. Anal. Calcd for
43.05; H, 6.27; N, 4.40. Found C, 42.67; H, 5.92; N, 4.40.
C57H83N5O38.8H2O: C,
4.7. Synthesis of flavinium catalysts 6–12
4.7.1. 3-{[N-(6-Deoxy-
5-ethyl-10-methylisoalloxazin-5-ium perchlorate 6
Conjugate 27 (4.78 mg; 3.8 mol) and acetaldehyde (60
1 mmol) were dissolved in a mixture of ethanol (320 L), water
(250 L), and 0.1 M HClO4 (320 L). The mixture was degassed
a-cyclodextrin-6-yl)carbamoyl]methyl}-
l
lL;
l
l
l
by a vacuum–argon cycle, after which palladium on charcoal
(10% w/w, 0.51 mg) was added. The reaction mixture was placed
into an autoclave equipped with a magnetic stirring bar and hydro-
gen was introduced (6 bar) for 24 h. The palladium was then fil-
tered off, after which ethanol and the residual acetaldehyde were
evaporated off under reduced pressure. The resulting solution of
6 was diluted to 2 mL. The concentration of the catalyst in the stock
solution was recalculated with respect to the concentration of the
conjugates prior to the alkylation and the actual volume of the
sample. MS (ESI) calcd for C51H74N5O32 [M+Na]+ m/z 1291.4; found
1292.0. UV–VIS (1 M HCl): 272 nm, 301 nm, 351 nm, 460 nm; after
addition of excess of H2O2: 395 nm, 533 nm.
4.7.2. 10-{3-[N-(6-Deoxy-
5-ethyl-3-methylisoalloxazin-5-ium perchlorate 7
Acetaldehyde (170 L, 3.03 mmol) and palladium on carbon
(10%, 2.5 mg, 2.52 mol) were added to solution of 28
(14.55 mg, 10.5 mol, calculated for the heptahydrate) in ethanol
L), perchloric acid (0.1 M in water, 800 L), and water
L). The resulting mixture was stirred for 21 h in the auto-
a-cyclodextrin-6-yl)carbamoyl]ethyl}-
l
l
a
l
(800
(600
l
l
l
clave under a hydrogen atmosphere (0.7 MPa) at room tempera-
ture. The palladium was then filtered off, and ethanol and the